Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D.
Derré L, et al. Among authors: lucca i.
J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020.
J Immunother Cancer. 2023.
PMID: 38101861
Free PMC article.